Title:Nanodrugs as a New Approach in the Therapy of Cardiovascular Diseases and Cancer with Tumor-associated Angiogenesis
Volume: 28
Issue: 27
Author(s): Justyna Hajtuch, Karolina Niska and Iwona Inkielewicz-Stepniak*
Affiliation:
- Department of Pharmaceutical Pathophysiology, Medical University of Gdansk, Debinki 1, 80-211 Gdansk,Poland
Keywords:
Nanodrugs, cardiovascular diseases, cancer, angiogenesis, nanomedicine, chemotherapeutics.
Abstract:
Background: Cancer, along with cardiovascular diseases, is globally defined
as the leading cause of death. Importantly, some risk factors are common to these diseases.
The process of angiogenesis and platelet aggregation is observed in cancer development
and progression. In recent years, studies have been conducted on nanodrugs for these
diseases that have provided important information on the biological and physicochemical
properties of nanoparticles. Their attractive features are that they are made of biocompatible,
well-characterized, and easily functionalized materials. Unlike conventional drug
delivery, sustained and controlled drug release can be obtained by using nanomaterials.
Methods: In this article, we review the latest research to provide comprehensive information
on nanoparticle-based drugs for the treatment of cancer, cardiovascular disease associated
with abnormal haemostasis, and the inhibition of tumor-associated angiogenesis.
Results: The results of the analysis of data based on drugs with nanoparticles confirm
their improved pharmaceutical and biological properties, which give promising antiplatelet,
anticoagulant, and antiangiogenic effects. Moreover, the review included in
vitro, in vivo research and presented nanodrugs with chemotherapeutics approved by
Food and Drug Administration.
Conclusion: By the optimization of nanoparticle size and surface properties, nanotechnology
is able to deliver drugs with enhanced bioavailability in treatment of cardiovascular
disease, cancer and inhibition of cancer-related angiogenesis. Thus, nanotechnology can
improve the therapeutic efficacy of the drug, but there is a need for a better understanding
of the nanodrugs interaction in the human body because this is a key factor in the success
of potential nanotherapeutics.
